the discovery and development of liraglutide and semaglutide Approaches for half-life extension GLP-1 agonists. (a) Structure and half-lives of native
Description
It was developed back in 2012, as a treatment for people with type 2 diabetes, but it took almost 5 years before it was FDA-approved for use
These are typically transient and fade within a few weeks
Neither incorporates genetic testing routinely
It is intended solely for laboratory experimentation and in vitro studies
